Complera (Rilpivirine/Tenofovir Disoproxil Fumarate/FTC)

The Latest

An Overview of Complera (Rilpivirine/Tenofovir/Emtricitabine)

Looking for a breakdown of the most important info to know about Complera, the newest once-daily, fixed-dose combination drug approved in the U.S. for first-line treatment? The government resource AIDSinfo has compiled this fact sheet that explains h...

By AIDSinfo

One-a-Day HIV Treatments: How Do They Compare? (Infographic)

Just one pill a day to control HIV? This once-fanciful idea became a reality in 2006, when Atripla was approved as the first single-tablet HIV medication regimen in the U.S. A single-tablet regimen (STR) contains meds from different drug classes and ...

Complera/Eviplera (Rilpivirine + Emtricitabine + Tenofovir)

What Is Complera? Who Should Take Complera? Who Should Not Take Complera? What About Drug Resistance? How Is Complera Taken? What Are the Side Effects? How Does Complera React With Other Drugs?

What Is Complera?

Complera is a tablet t...

By AIDS InfoNet


Brand name: Complera

Generic name: rilpivirine/emtricitabine/tenofovir, or RPV/FTC/TDF

Class: NNRTI and NRTI -- single-tablet regimen (STR)

Manufacturer: Gilead Sciences,, (800) GILEAD-5 (445-3235)

AWP: $2,195.83/month; ADAP/Public...

By Positively Aware

Complera, My New 1-Pill-a-Day Regimen (and My Rosacea Diagnosis): A Video Blog Entry by Justin B. Terry-Smith

Please note: My rosacea diagnosis is not connected to my taking Complera. I just chose to blog about them at the same time.

In 2008 I started my HIV medications. My first regimen was Truvada, Reyataz, and Norvir -- a three-pill-a-day regimen that my...

By Justin B. Terry-Smith

FDA Approves Complera (Edurant + Truvada), a Second "All-in-One" Option for First-Line HIV Treatment

When it comes to single-pill HIV treatment regimens in the U.S., Atripla is no longer the only game in town. The U.S. Food and Drug Administration has just approved Complera, a once-daily tablet that contains Truvada (tenofovir/FTC) and the NNRTI Edu...

By Myles Helfand

B-Tripla and a Bluey on Bondi Beach: A Blog Entry by Bob Frascino, M.D.

"It's been three years since the last new antiretrovirals hit the market. ... The good news is that a new NNRTI is on its way to pharmacy shelves very soon." Bob Frascino, M.D., returns from his vacation in Australia with a hilarious and informative ...

By Bob Frascino, M.D.